Prevention of Side effects associated with COVID 19 Vaccinations: A Review
DOI:
https://doi.org/10.22270/ajprd.v13i1.1524Abstract
Globally, the new SARS-CoV-2, which is responsible for COVID-19, represents a considerable burden on both health and the economy. Although there have been a great number of clinical investigations, there is not yet a single therapy or medicine that has been licensed for successful treatment. Over 300 million people have lost their lives as a result of the COVID-19 epidemic, and there is an increasing demand for anti-viral medication. Following the COVID-19 pandemic, extensive international research has led to the development of effective vaccines. However, due to the crisis, some potential side effects have been overlooked. Common complications include cerebrovascular disorders, transient ischemic attacks, intracerebral hemorrhage, ischemic stroke, and demyelinating disorders. These effects are often acute and transient but can be severe and even fatal in a few cases. This review examines the immunological and autoimmune adverse events associated with COVID-19 vaccines, highlighting their frequencies, reported cases, and associations with specific vaccine classes. The concept of vaccine-induced immune thrombotic thrombocytopenia is crucial in addressing vaccine skepticism. Healthcare professionals and public health agencies must actively monitor and address these adverse events promptly disclose suspicious incidents, take measures to mitigate dangers, and inform the public with transparency and accurate information. Continuing research and surveillance are essential for understanding the underlying mechanisms of these adverse events and developing strategies to minimize their occurrence.
Downloads
References
Zhao W, Zhang J, Meadows ME, Liu Y, Hua T, Fu B (2020) A systematic approach is needed to contain COVID-19 globally. Sci Bull 65(11):876–878.
WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organisation (WHO). 2020;
Patel SKS, Lee JK, Kalia VC (2020) Deploying biomolecules as antii-COVID-19 agents. Indian J Microbiol 60:263–268.
Rishi P, Thakur K, Vij S, Rishi L, Singh A, Kaur IP, Patel SKS, Lee JK, Kalia VC (2020) Diet, gut microbiota and COVID-19. Indian J Microbiol 60:420–429.
Kalia VC, Raju SC, Purohit HJ (2011) Genomic analysis reveals versatile organisms for quorum quenching enzymes: acyl-homoserine lactone-acylase and-lactonase. Open Microbiol J 5:1–11.
Kalia VC, Wood TK, Kumar P (2014) Evolution of resistance to quorum-sensing inhibitors. Microb Ecol 68:13–23.
Kumar P, Patel SKS, Lee JK, Kalia VC (2013) Extending the limits of Bacillus for novel biotechnological applications. Biotechnol Adv 31:1543–1561.
Lythgoe MP, Middleton P (2020) Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci 41(6):363–382.
Desai A, Kulkarni A, Rajkumar SV, Gyawali B (2020) Clinical trial endpoints in severe COVID-19. Mayo Clin Proc 95(8):1578–1580.
Kupferschmidt K, Cohen J (2020) WHO launches global megatrial of the four most promising coronavirus treatments? Sci Mag.
Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G (2020) COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev 53:66–70.
Joppi R, Bertele V, Vannini T, Garattini S, Banzi R (2020) Food and drug administration vs European medicines agency: review times and clinical evidence on novel drugs at the time of approval. Br J Clin Pharmacol 86:170–174.
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R (2020) COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 24:91–98.
Xian Y, Zhang J, Bian Z, Zhou H, Zhang Z, Lin Z, Xu H (2020) Bioactive natural compounds against human coronaviruses: a review and perspective. Acta Pharma Sin B 10(7):1163–1174.
Tian, H. Y., Ruan, L. J., Yu, T., Zheng, Q. F., Chen, N. H., Wu, R. B., et al. Bufospirostenin A and Bufogargarizin C, steroids with rearranged skeletons from the toad Bufo bufo gargarizans. J. Nat. Prod. 2017; 80 (4), 1182–1186.
Shen, Y., Cai, H., Ma, S., Zhu, W., Zhao, H., Li, J., et al. Telocinobufagin has antitumor effects in non-small-cell lung cancer by inhibiting STAT3 signaling. J. Nat. Prod. 2022; 85 (4), 765–775.
Panggabean, J. A., Adiguna, S. B. P., Rahmawati, S. I., Ahmadi, P., Zainuddin, E. N., Bayu, A., et al. Antiviral activities of algal-based sulfated polysaccharides. Molecules 2022; 27 (4), 1178.
Prassas, I., and Diamandis, E. P. Novel therapeutic applications of cardiac glycosides. Nat. Rev. Drug Discov. 2008; 7 (11), 926–935.
S. Banerjee, A.O. Kaseb, Z. Wang, D. Kong, M. Mohammad, S. Padhye, F. H. Sarkar, R.M. Mohammad, Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer, Cancer Res. 69 (13) (2009) 5575–5583.
K. Chaieb, B. Kouidhi, H. Jrah, K. Mahdouani, A. Bakhrouf, Antibacterial activity of Thymoquinone, an active principle of Nigella sativa and its potency to prevent bacterial biofilm formation, BMC Complement. Altern. Med. 11 (2011) 29.
Ahmad, R.K. Mishra, A. Vyawahare, A. Kumar, M.U. Rehman, W. Qamar, A. Q. Khan, R. Khan, Thymoquinone (2-Isoprpyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/anticancer agent: Chemistry and biological effects, Saudi Pharm. J. 27 (8) (2019) 1113–1126.
M. Khader, P.M. Eckl, Thymoquinone: an emerging natural drug with a wide range of medical applications, Iran. J. Basic Med. Sci. 17 (12) (2015) 950–957.
M. El Gazzar, R. El Mezayen, J.C. Marecki, M.R. Nicolls, A. Canastar, S.C. Dreskin, Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation, Int. Immunopharmacol. 6 (7) (2006) 1135–1142.
K. Ikeda, K. Tsujimoto, M. Uozaki, M. Nishide, Y. Suzuki, A.H. Koyama, H. Yamasaki, Inhibition of multiplication of herpes simplex virus by caffeic acid, Int. J. Mol. Med. 28 (4) (2011) 595–598.
J.J. Meyer, A.J. Afolayan, M.B. Taylor, D. Erasmus, Antiviral activity of galangin isolated from the aerial parts of Helichrysum aureonitens, J. Ethnopharmacol. 56 (2) (1997) 165–169.
J.R. Weng, C.S. Lin, H.C. Lai, Y.P. Lin, C.Y. Wang, Y.C. Tsai, K.C. Wu, S.H. Huang, C.W. Lin, Antiviral activity of Sambucus FormosanaNakai ethanol extract and related phenolic acid constituents against human coronavirus NL63, Virus Res. 273 (2019), 197767.
G.F. Wang, L.P. Shi, Y.D. Ren, Q.F. Liu, H.F. Liu, R.J. Zhang, Z. Li, F.H. Zhu, P. L. He, W. Tang, P.Z. Tao, C. Li, W.M. Zhao, J.P. Zuo, Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro, Antivir. Res. 83 (2) (2009) 186–190.
M.A.I. Al-Hatamleh, M.M. Hatmal, K. Sattar, S. Ahmad, M.Z. Mustafa, M.D. C. Bittencourt, R. Mohamud, Antiviral and immunomodulatory effects of phytochemicals from honey against COVID-19: potential mechanisms of action and future directions, Molecules 25 (2020) 21.
D.D. Singh, D.K. Yadav, TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy, Biomedicines 9 (2021) 8.
A.A. Turab Naqvi, G.M. Hasan, M.I. Hassan, Targeting tau hyperphosphorylation via kinase inhibition: strategy to address Alzheimer’s disease, Curr. Top. Med. Chem. 20 (12) (2020) 1059–1073.
Kowalczyk, M. Przychodna, S. Sopata, A. Bodalska, I. Fecka, Thymol and thyme essential oil-new insights into selected therapeutic applications, Molecules 25 (2020) 18.
S.A. Kulkarni, S.K. Nagarajan, V. Ramesh, V. Palaniyandi, S.P. Selvam, T. Madhavan, Computational evaluation of major components from plant essential oils as potent inhibitors of SARS-CoV-2 spike protein, J. Mol. Struct. 1221 (2020), 128823.
P.K. Yadav, A. Jaiswal, R.K. Singh, In silico study on spice-derived antiviral phytochemicals against SARS-CoV-2 TMPRSS2 target, J. Biomol. Struct. Dyn. (2021) 1–11.
R. Rolta, D. Salaria, P. Sharma, B. Sharma, V. Kumar, B. Rathi, M. Verma, A. Sourirajan, D.J. Baumler, K. Dev, Phytocompounds of Rheum emodi, Thymus serpyllum, and Artemisia annua inhibit spike protein of SARS-CoV-2 binding to ACE2 receptor: in silico approach, Curr. Pharmacol. Rep. (2021) 1–15.
S. Qazi, K. Sheikh, K. Raza, In silico approach to understand the epigenetic mechanism of SARS-CoV-2 and its impact on the environment, Virusdisease (2021) 1–12.
M. Ghasemzadeh Rahbardar, H. Hosseinzadeh, Effects of rosmarinic acid on nervous system disorders: an updated review, Naunyn Schmiede Arch. Pharmacol. 393 (10) (2020) 1779–1795.
S. Kumar, P. Kashyap, S. Chowdhury, S. Kumar, A. Panwar, A. Kumar, Identification of phytochemicals as potential therapeutic agents that binds to Nsp15 protein target of coronavirus (SARS-CoV-2) that are capable of inhibiting virus replication, Phytomedicine 85 (2020), 153317.
J. Selvaraj, U.V. Rekha, S.F. Jh, V. Sivabalan, R. Ponnulakshmi, V. Vishnupriya, M. Kullappan, R.N. Sreekandan, S.K. Mohan, Molecular docking analysis of SARSCoV-2 linked RNA dependent RNA polymerase (RdRp) with compounds from Plectranthus amboinicus, Bioinformation 17 (1) (2021) 167–170.
M. Petersen, M.S. Simmonds, Rosmarinic acid, Phytochemistry 62 (2) (2003) 121–125.
C. Colica, L. Di Renzo, V. Aiello, A. De Lorenzo, L. Abenavoli, Rosmarinic acid as potential anti-inflammatory agent, Rev. Recent Clin. Trials 13 (4) (2018) 240–242.
M. Hitl, N. Kladar, N. Gavari´c, B. Boˇzin, Rosmarinic acid-human pharmacokinetics and health benefits, Planta Med. 87 (4) (2020) 273–282.
A.G. Junior, S. Tolouei, F.A. Dos Reis Lívero, F. Gasparotto, T. Boeing, P. de Souza, Natural agents modulating ACE-2: a review of compounds with potential against SARS-CoV-2 infections, Curr. Pharm. Des. 27 (13) (2021) 1588–1596.
S. Banerjee, A.O. Kaseb, Z. Wang, D. Kong, M. Mohammad, S. Padhye, F. H. Sarkar, R.M. Mohammad, Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer, Cancer Res. 69 (13) (2009) 5575–5583.
J. Selvaraj, U.V. Rekha, S.F. Jh, V. Sivabalan, R. Ponnulakshmi, V. Vishnupriya, M. Kullappan, R.N. Sreekandan, S.K. Mohan, Molecular docking analysis of SARSCoV-2 linked RNA dependent RNA polymerase (RdRp) with compounds from Plectranthus amboinicus, Bioinformation 17 (1) (2021) 167–170.
D.D. Singh, I. Han, E.H. Choi, D.K. Yadav, Recent advances in pathophysiology, drug development and future perspectives of SARS-CoV-2, Front. Cell Dev. Biol. 8 (2020), 580202.
D.D. Singh, I. Han, E.H. Choi, D.K. Yadav, Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2, Comput. Struct. Biotechnol. J. 18 (2020) 3774–3787.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Haridhnya S Deshmukh, Shruti S Khodke, Payal S Raut, Aijaz A. Sheikh, Kailash. R. Biyani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.